decitabine/cedazuridine
Sign in to saveDecitabine/cedazuridine, sold under the brand name Inqovi among others, is a fixed-dose combination anticancer medication used for the treatment of adults with myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML). It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.
In the Vinony graph
Within Vinony's link graph, decitabine/cedazuridine is referenced by 3 other articles, and connects out to chemotherapy, oral administration and tiazofurin.
Vinony files it under Cancer treatments, Chemical pages without ChemSpiderID and Chemical pages without DrugBank identifier.
Its subject is documented across 5 Wikipedia language editions.
~5 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- History
- References
- External links
Decitabine/cedazuridine, sold under the brand name Inqovi among others, is a fixed-dose combination anticancer medication used for the treatment of adults with myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML). It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.
The most common side effects of decitabine/cedazuridine include fatigue, constipation, hemorrhage, muscle pain (myalgia), mucositis (mouth sores), arthralgia (joint pain), nausea, dyspnea, diarrhea, rash, dizziness, fever with low white blood cell count (febrile neutropenia), edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased. The combination can cause fetal harm. It is taken by mouth.
Excerpted from Wikipedia’s “decitabine/cedazuridine” article, available under the CC BY-SA 4.0 licence.